June 21, 2022
1 min watch
Save
VIDEO: Impact of stem cell transplants in myeloma treatment ‘remarkable’
In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.
Richardson discusses one of the major findings of the study, which was a significant difference between the length of progression-free survival between the early transplant arm of the cohort and the no-transplant arm.
“This was really encouraging and we thought quite remarkable, and to some extent unexpected,” Richardson said. “We expected at least a year, but we saw substantially more than that.”
Reference:
- Richardson P, et al. Presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Richardson reports consulting for and/or receiving research support from AstraZeneca, Celgene/BMS, GSK, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio and Takeda.
Read more about